Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
3.79
Nov 20 • 3:59 PM ET Dollar change-0.21 Percentage change(-5.25%)
Aftermarket Close
3.79
Aftermarket • 4:15 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
237.84M
Enterprise Value
119.04M
Income
-121.10M
Sales
5.32M
Book/sh
1.71
Cash/sh
2.00
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
48
IPO
Oct 11, 2024
P/E
-
Forward P/E
-
PEG
-
P/S
44.71
P/B
2.22
P/C
1.90
P/FCF
-
EV/EBITDA
-
EV/Sales
22.38
Quick Ratio
6.42
Current Ratio
6.42
Debt/Eq
0.06
LT Debt/Eq
0.05
Option/Short
No / Yes
EPS (ttm)
-2.04
EPS next Y
-0.75
EPS next Q
-0.18
EPS this Y
50.27%
EPS next Y
42.81%
EPS next 5Y
34.18%
EPS past 3/5Y
-5.31% -
Sales past 3/5Y
- -
EPS Y/Y TTM
16.95%
Sales Y/Y TTM
39.93%
EPS Q/Q
33.74%
Sales Q/Q
138.87%
Insider Own
50.81%
Insider Trans
-1.69%
Inst Own
68.35%
Inst Trans
0.71%
ROA
-109.89%
ROE
-146.12%
ROIC
-108.20%
Gross Margin
64.00%
Oper. Margin
-1001.05%
Profit Margin
-2276.33%
SMA20
-3.26%
SMA50
-0.82%
SMA200
-9.94%
Trades
Shs Outstand
62.75M
Shs Float
30.87M
52W High
7.75 -51.10%
52W Low
2.90 30.69%
Volatility
11.51% 9.83%
ATR (14)
0.37
RSI (14)
47.69
Beta
0.25
Rel Volume
0.37
Avg Volume
241.91K
Volume
88,481
Perf Week
-0.26%
Perf Month
11.80%
Perf Quarter
-12.27%
Perf Half Y
-15.96%
Perf YTD
-38.17%
Perf Year
7.98%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
4.00
Price
3.79
Change %
-5.25%
Consensus
Strong Buy
Avg. Price Target
$9.90
Implied Upside
+161.2%
Analysts10incl. previous ratings
Rating Distribution10 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 23, 2026Initiated
RJF logoRRaymond James
Strong Buy$10+163.9%
Oct 15, 2026Initiated
NNeedham
Buy$8+111.1%
Oct 05, 2026Initiated
OPY logoOOppenheimer
Outperform$15+295.8%
Jun 16, 2026Upgrade
JPM logoJJP Morgan
Neutral → Overweight$9+137.5%
Jun 10, 2026Initiated
CChardan Capital Markets
Buy$6.50+71.5%
Apr 14, 2026Initiated
RRodman & Renshaw
Buy$7+84.7%
Oct 02, 2025Initiated
CCantor Fitzgerald
Overweight$7+84.7%
Sep 16, 2025Downgrade
JPM logoJJP Morgan
Overweight → Neutral
May 27, 2025Initiated
WWedbush
Outperform$8+111.1%
Nov 05, 2024Initiated
WWilliam Blair
Outperform
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gold KellyChief Financial OfficerAug 31 '26Buy3.9610,00039,60010,000Sep 02 07:50 PM
Schwab Andrew J.DirectorAug 27 '26Sale4.04400,0001,616,0002,033,270Aug 31 05:05 PM
Schwab Andrew J.DirectorAug 24 '26Sale4.5010452,433,270Aug 26 04:57 PM
Schwab Andrew J.DirectorAug 20 '26Sale4.54114,700520,7382,465,298Aug 21 04:59 PM
Schwab Andrew J.DirectorAug 19 '26Sale4.7645,147214,9002,579,998Aug 21 04:59 PM
Schwab Andrew J.DirectorAug 21 '26Sale4.5032,018144,0812,433,280Aug 21 04:59 PM
Tardiff DanielChief Scientific OfficerAug 19 '26Sale4.761,7388,2730Aug 19 08:46 PM
Daniel TardiffaffiliateAug 19 '26Proposed Sale4.761,7388,276Aug 19 10:23 AM
Young Richard ADirectorAug 03 '26Buy1.6516,37827,024186,388Aug 05 05:09 PM
Maricich YuriChief Medical OfficerAug 03 '26Buy1.656,55110,80912,611Aug 05 05:08 PM
Gold KellyChief Financial OfficerAug 03 '26Buy1.656,55110,80974,428Aug 05 05:08 PM
Mandel-Brehm JoshChief Executive OfficerAug 03 '26Buy1.656,55110,809284,968Aug 05 05:07 PM
CAMP4 Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a class of RNA-targeting therapeutics for upregulating gene expression and restoration of healthy protein levels to treat a broad range of genetic diseases. Its lead product candidate is CMP-002. The company was founded by Richard A. Young and Leonard Zon in 2015 and is headquartered in Cambridge, MA.
CEOMr. Joshua Mandel-Brehm
Founder & Independent DirectorDr. Richard A. Young Ph.D.
Chief Financial OfficerMs. Kelly Gold
M.D.Dr. Yuri Maricich M.B.A.
Founder & Chairman of Scientific Advisory BoardDr. Leonard I. Zon M.D.